The therapeutic landscape for non–small cell lung cancer (NSCLC) has been relatively stable since the 2016 approval of pembrolizumab, but results presented at the 2024 World Conference on Lung Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results